SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: semi_infinite who wrote (2796)6/20/2011 5:39:03 PM
From: DewDiligence_on_SI   of 3027
 
>If MNTA cannot overturn Teva's patents then it will be 2014 or later before we see a generic.<

Not necessarily. Because the statutory Hatch-Waxman stay has expired, NVS/MNTA can launch generic Copaxone as soon as they get FDA approval. If NVS/MNTA do get FDA approval, I expect Teva to settle the Copaxone patent case in short order—see siliconinvestor.com .

p.s. Discussions addressing your other numbered points can be found in the MNTA ReadMeFirst at siliconinvestor.com .
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News